The safety, tolerability and pharmacokinetics of levamisole alone, levamisole plus ivermectin, and levamisole plus albendazole, and their efficacy against Onchocerca volvulus

References

• Ali, M. M. M., Mukhtar, M. M., Baraka, O. Z., Homeida, M. M. A., Kheir, M. M. & Mackenzie, C. D. (2002). Immunocompetence may be important in the effectiveness of Mectizan® (ivermectin) in the treatment of human onchocerciasis. Acta Tropica, 84, 49–53.
   Google Scholar
• Ali, M. M., Baraka, O. Z., Abdelrahman, S. I., Sulaiman, S. M., Williams, J. F., Homeida, M. M. & Mackenzie, C. D. (2003). Immune responses directed against microfilariae correlate with severity of clinical onchodermatitis and treatment history. Journal of Infectious Diseases, 187, 714–717.
   PubMed Web of Science ®Google Scholar
• Anon. (1999). Guidance for Industry. In Vivo Drug Metabolism/ drug Interaction Studies — Study Design, Data Analysis, and Recommendations for Dosing and Labeling. Rockville, MD: Center for Drug Evaluation and Research, Food and Drug Administration.
   Google Scholar
• Awadzi, K. (1980). The chemotherapy of oncho-cerciasis. II. Quantitation of the clinical reaction to microfilaricides. Annals of Tropical Medicine and Parasitology, 74,189–197.
   PubMed Web of Science ®Google Scholar
• Awadzi, K., Schulz-Key, H., Howells, R. E., Haddock, D. R. W. & Gilles, H. M. (1982). The chemotherapy of onchocerciasis. VIII. Levamisole and its com-bination with the benzimidazoles. Annals of Tropical Medicine and Parasitology, 76,459–473.
   PubMed Web of Science ®Google Scholar
• Awadzi, K., Dadzie, K. Y., de Sole, G. & Remme, J. (1990a). Reactions to ivermectin treatment in onchocerciasis patients. Acta Leidensia, 59, 193–199.
   PubMedGoogle Scholar
• Awadzi, K., Schulz Key, H., Edwards, G., Breckenridge, A., Orme, M. & Gilles, H. (1990b). The chemotherapy of onchocerciasis. XIV. Studies with mebendazole citrate. Tropical Medicine and Parasitology, 41, 383–386.
   PubMedGoogle Scholar
• Awadzi, K., Hero, M., Opoku, O., Buttner, D. W. & Gilles, H. M. (1991). The chemotherapy of onchocerciasis. XV. Studies with albendazole. Tropical Medicine and Parasitology, 42, 356–360.
   PubMedGoogle Scholar
• Awadzi, K., Hero, M., Opoku, N. O., Buttner, D. W., Coventry, P. A., Prime, M. A., Orme, M. L. & Edwards, G. (1994). The chemotherapy of onchocer-ciasis. XVII. A clinical evaluation of albendazole in patients with onchocerciasis; effects of food and pretreatment with ivermectin on drug response and pha=acokinetics. Tropical Medicine and Parasitology,45, 203–208.
   PubMedGoogle Scholar
• Awadzi, K., Addy, E. T., Opoku, N. O., Plenge-Bonig, A. & Buttner, D. W. (1995a). The chemotherapy of onchocerciasis. XX. Ive=ectin in combination with albendazole. Tropical Medicine and Parasitology, 46, 213–220.
   PubMedGoogle Scholar
• Awadzi, K., Opoku, N. O., Addy, E. T. & Quartey, B. T. (1995b). The chemotherapy of onchocerciasis. XIX. The clinical and laboratory tolerance of high dose ivermectin. Tropical Medicine and Parasitology, 46, 131–137.
   PubMedGoogle Scholar
• Awadzi, K., Opoku, N. O., Attah, S. K., Addy, E. T., Duke, B. O., Nyame, P. K. & Kshirsagar, N. A. (1997). The safety and efficacy of amocarzine in African onchocerciasis and the influence of ivermectin on the clinical and parasitological response to treat-ment. Annals of Tropical Medicine and Parasitology, 91, 281–296.
   PubMed Web of Science ®Google Scholar
• Awadzi, K., Attah, S. K., Addy, E. T., Opoku, N. O. & Quartey, B. T. (1999). The effects of high-dose ivermectin regimens on Onchocerca volvulus in oncho-cerciasis patients. Transactions of the Royal Society of Tropical Medicine and Hygiene, 93,189–194.
   PubMed Web of Science ®Google Scholar
• Awadzi, K., Edwards, G., Duke, B. O. L., Opoku, N. O., Attah, S. K., Addy, E. T., Ardrey, A. E. & Quartey, B. T. (2003). The co-administration of iver-mectin and albendazole — safety, pharmacokinetics and efficacy against Onchocerca volvulus. Annals of Tropical Medicine and Parasitology, 97,165–178.
   PubMed Web of Science ®Google Scholar
• Chavasse, D. C., Post, R. J., Lemoh, P. A. & Whitworth, J. A. (1992). The effect of repeated doses of ivermectin on adult female Onchocerca volvulus in Sierra Leone. Tropical Medicine and Parasitology, 43, 256–262.
   PubMedGoogle Scholar
• Duke, B. O., Zea-Flores, G., Castro, J., Cupp, E. W. & Munoz, B. (1992). Effects of three-month doses of ivermectin on adult Onchocerca volvulus. American Journal of Tropical Medicine and Hygiene, 46, 189–194.
   PubMed Web of Science ®Google Scholar
• Edwards, G., Dingsdale, A., Helsby, N., Orme, M. L. & Breckenridge, A. M. (1988). Relative systemic avail-ability of ivermectin after administration as capsule, tablet and oral solution. European Journal of Clinical Pharmacology, 35,681–684.
   PubMed Web of Science ®Google Scholar
• Gardon, J., Boussinesq, M., Kamgno, J., Gardon-Wendel, N., Demanga, N. & Duke, B. O. (2002). Effects of standard and high doses of ivermectin on adult worms of Onchocerca volvulus: a randomised controlled trial. Lancet, 360,203–210.
   PubMed Web of Science ®Google Scholar
• Hero, M., Bird, A. C. & Awadzi, K. (1992). Quantifica-tion of the ocular reactions to microfilaricides in the chemotherapy of onchocerciasis. Eye, 6,93–96.
   PubMed Web of Science ®Google Scholar
• Hoaksey, P. E., Awadzi, K., Ward, S. A., Coventry, P. A., Orme, M. L. & Edwards, G. (1991). Rapid and sensitive method for the determination of albendazole and albendazole sulphoxide in biological fluids. Journal of Chromatography, 566,244–249.
   PubMed Web of Science ®Google Scholar
• Klager, S. L., Whitworth, J. A. & Downham, M. D. (1996). Viability and fertility of adult Onchocerca volvulus after 6 years of treatment with ivermectin. Tropical Medicine and International Health, 1, 581–589.
   PubMed Web of Science ®Google Scholar
• Kouassi, E., Caille, G., Lariviere, L. & Vezina, M. (1986). Novel assay and pharmacokinetics of levamisole and p-hydroxylevamisole in human plasma and urine. Biopharmaceutics and Drug Disposition, 7,71–89.
   PubMed Web of Science ®Google Scholar
• Kwei, G. Y., Alvaro, R. F., Chen, Q., Jenkins, H. J., Hop, C. E. A. C., Keohane, C. A., Ly, V. T., Strauss, J. R., Wang, R. W., Wang, Z., Pippert, T. R. & Umbenhauer, D. R. (1999). Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in MDRA1A p-glycoprotein. Drug Metabolism and Disposition: the Biological Fate of Chemicals, 27, 581–587.
   PubMed Web of Science ®Google Scholar
• Merino, G., Alvarez, A. I., Prieto, J. G. & Kim, R. B. (2002). The anthelminthic agent albendazole does not interact with p-glycoprotein. Drug Metabolism and Disposition: the Biological Fate of Chemicals, 30, 365–369.
   PubMed Web of Science ®Google Scholar
• Ottesen, E. A. (1995). Immune responsiveness and the pathogenesis of human onchocerciasis. Journal of Infectious Diseases, 171,659–671.
   PubMed Web of Science ®Google Scholar
• Rawden, H. C. (1999). An investigation of potential chemotherapeutic drug combinations with albendazole for the treatment of Echinococcus infection. Ph.D. thesis, Department of Pharmacology and Therapeutics, The University of Liverpool, Liverpool, U.K.
   Google Scholar
• Rawden, H. C., Kokwaro, G. O., Ward, S. A. & Edwards, G. (2000). Relative contribution of cyto-chromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes. British Journal of Clinical Pharmacology, 49, 313–322.
   PubMed Web of Science ®Google Scholar
• Renoux, G. (1980). The general immunopharmacology of levamisole. Drugs, 20,89–99.
   PubMed Web of Science ®Google Scholar
• Taylor, H. R., Awadzi, K., George, T., Schulz-Key, H. & Murphy, R. P. (1985). Fluorescein angiographic studies of mebendazole treatment for onchocerciasis. Tropical Medicine and Parasitology, 36,7–11.
   PubMedGoogle Scholar
• World Health Organization (1987). WHO Expert Committee on Onchocerciasis. Third Report. Technical Report Series No. 752. Geneva: WHO.
   Google Scholar
• World Health Organization (1995). Onchocerciasis and its Control. Report of a WHO Expert Committee on Onchocerciasis Control. Technical Report Series No. 852. Geneva: WHO.
   Google Scholar